How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Drug Repurposing Market
- By Drug Type: Small Molecule Drugs, Biologics, Peptides, Nucleic Acid-based Drugs
- By Therapeutic Area: Oncology, Neurology, Cardiovascular Diseases, Infectious Diseases, Autoimmune Disorders
- By Repurposing Approach: Computational Drug Repurposing, Experimental Screening, Clinical Data Mining, Phenotypic Screening
- By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes
- By Application: New Indications Discovery, Combination Therapy Development, Safety Profiling, Drug Rescue
Key Highlights
A snapshot of what the full report proves- 01 Market size - USD 3.48 Billion global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Small Molecule Drugs leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Market Definition
Drug repurposing is the systematic identification and clinical redeployment of an existing, approved or investigational therapeutic compound for a new medical indication. The practice uses the original molecular entity as its core, leveraging known safety, pharmacokinetics and formulation characteristics to adapt the compound to a different disease context. Drug repurposing workflows integrate preclinical data mining, mechanistic pharmacology, computational screening, and regulatory strategy to reposition a molecule within the pharmaceutical value chain. The subject sits between discovery and development, shortening the distance from bench to clinical application by substituting de novo chemistry with repositioning of an established therapeutic agent. Drug repurposing therefore operates as a translational bridge that repackages existing pharmacological assets for unmet or underserved therapeutic needs.
The principal types of drug repurposing are on-target repurposing, off-target repurposing, formulation-based repurposing, and combination repurposing. On-target repurposing retains the original mechanism of action and applies the drug to a different disease where that mechanism is relevant, while off-target repurposing exploits secondary pharmacology to treat conditions unrelated to the initial indication. Formulation-based repurposing alters delivery mode, such as changing an oral tablet to an inhaled aerosol or topical formulation to reach a new tissue compartment. Combination repurposing pairs an existing drug with another agent to achieve synergy or to overcome resistance. These types are distinguished by biochemical specificity, tissue exposure, dose constraints, and regulatory precedent, attributes that determine how readily a compound can be repositioned for another clinical use.
Drug repurposing programs are executed by mining clinical and preclinical evidence, performing target validation and dose-translation studies, and then conducting focused clinical trials to demonstrate efficacy in the new indication. The process typically begins with computational repurposing or phenotypic screening, followed by in vitro and in vivo validation, pharmacokinetic bridging studies and adaptive or basket trial designs to efficiently test therapeutic hypotheses. Deliverables include revised regulatory dossiers, new investigator brochures and often novel formulations or companion diagnostics to select responsive patient subgroups. End users of repurposed drugs are clinicians across specialties, hospital systems, and payers that evaluate therapeutic value, as well as biotech and pharmaceutical sponsors that license or commercialize repositioned assets. Each step in development is tailored to minimize redundancy with the original approval package while generating the specific efficacy evidence required for label expansion or a new indication claim.
The value of drug repurposing lies in its ability to reduce technical, temporal and financial barriers to bringing a therapeutic benefit to patients for whom no approved treatment exists. By relying on established safety profiles and manufacturing pathways, repurposing shortens development timelines and lowers the scientific uncertainty associated with first-in-class discovery. For clinicians and health systems, repurposed drugs can fill therapeutic gaps rapidly, enable precision-use scenarios through dose or formulation adjustments, and offer alternative treatment options where standard therapies fail. For sponsors and investors, repurposing unlocks additional commercial potential from existing assets and can de-risk portfolios through incremental regulatory approvals or label extensions. Taken together, these attributes explain why drug repurposing is a sustained strategic approach within pharmaceutical development and clinical therapeutics.
Market Segmentation
The Drug Repurposing Market is segmented so the analysis exposes where demand concentrates and how value is distributed across the industry. Verified Market Intelligence structures the study across Drug Type, Therapeutic Area, Repurposing Approach, End User, Application, holding each axis separate so adoption, pricing and growth can be read on their own terms.
The figure above maps the full segmentation framework, including the regional split across North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Read together, these dimensions form the backbone for the deeper segment and geography chapters that follow, and they let a reader see at a glance how the Drug Repurposing Market is organised.
Research Timelines
Every figure in the Drug Repurposing Market study is anchored to a single, clearly defined research horizon so that estimates and forecasts stay consistent from one section to the next. The horizon runs from 2024 through 2033, and the timeline above shows how each year is classified. Fixing this window at the outset is what allows the sizing in the market chapters, the segment splits and the regional breakdowns to all be read on the same footing rather than against shifting reference points.
The historical period, 2024, captures verified actuals that establish where the Drug Repurposing Market stood before the outlook begins. These are drawn from published financials, trade and shipment records, association data and primary inputs, and they form the empirical foundation the rest of the model is calibrated against. Because the historical view is built from evidence rather than projection, it sets the reference level for measuring momentum into the base year and beyond.
The base year, 2025, is the anchor point from which all market sizing is measured, and the estimated year, 2026, carries that base into the most recent full-year view. The base year consolidates the actuals into a definitive market value, while the estimated year reflects the current state of demand using the latest available indicators. Separating the two keeps the confirmed baseline distinct from the near-term estimate, so readers can see exactly where certainty ends and projection begins.
The forecast period then runs from 2027 to 2033, projecting the Drug Repurposing Market forward on the strength of the base year value and the study growth outlook. Each forecast year is modelled on the same assumptions and compounded consistently, which is why the trajectory shown above rises smoothly rather than in isolated jumps. Holding the whole report to this one timeline is a core part of Verified Market Intelligence methodology, ensuring the numbers a reader compares across chapters always describe the same years and the same market.
Assumptions
Market assumptions for the Drug Repurposing Market define the specific conditions under which existing drugs, active pharmaceutical ingredients and known clinical formulations are evaluated for new therapeutic indications. These assumptions cover the services and products used in repurposing, including computational drug screening platforms, preclinical validation assays, regulatory dossier preparation, adaptive clinical trial designs and licensing or out-licensing arrangements, and they reflect end users such as biopharma repurposing teams, academic translational centres, contract research organisations and specialty licensing groups.
The senior research team and subject matter experts at Verified Market Intelligence set assumptions by triangulating primary interviews with repurposing practitioners, regulatory guidance relevant to cross-indication applications, patent and exclusivity landscapes, licensing deal flow observed in 2024, and proprietary data on platform adoption. Assumptions are stress-tested against alternative scenarios to keep model inputs conservative, evidence-based and defensible for forecast modelling through 2033.
| Assumption Category | Assumption | Impact on Market Dynamics | Model Application Area |
|---|---|---|---|
| Regulation and Policy | Regulatory acceptance of adaptive clinical trial designs for new indications of approved molecules | Shortens clinical development timelines for repurposed assets, increasing the number of programs that advance to late-stage trials and raising service demand for adaptive trial design and regulatory strategy providers | Forecast modelling, time-to-market adjustment, service revenue projection |
| Technology Adoption and Standards | Wider use of in silico repositioning platforms that integrate real-world evidence with molecular signatures | Shifts investment toward computational screening and decreases per-program preclinical cost, accelerating program throughput and favouring platform vendors over purely wet-lab CROs | Segment split, vendor revenue mix, operational cost inputs |
| Raw Material and Input Supply | Availability of reference API batches and formulation samples for bioequivalence and bridging studies | Constrained access to reference materials increases timeline and cost for bridging studies, reducing the number of low-cost repurposing opportunities and elevating prices for analytical and formulation services | Base year sizing, pricing inputs, probability of success adjustments |
| Distribution Channels | Prevalence of licensing and out-licensing deals between small biotech and mid-size pharma for repurposed indications | Increases transactional revenue for business development and licensing advisory services and concentrates commercial upside for mid-size pharma, shaping how value is captured across the ecosystem | Company share assignment, deal-driven revenue modelling, advisory service demand |
| End User Demand Behaviour | Prioritisation by academic translational centres of rare disease repositioning projects with orphan designation potential | Leads to a higher share of repurposing programs targeting orphan indications, boosting demand for regulatory orphan designation support and small, targeted clinical trials | Regional allocation, therapeutic segment sizing, trial service demand forecasts |
Limitations
Study limitations in the context of drug repurposing focus on the process of identifying new therapeutic uses for existing drugs. The subject produces data on clinical trial repositioning outcomes, preclinical pharmacology, regulatory repositioning pathways, licensing and collaboration deals, and therapeutic area incidence, and some of these measures are difficult to quantify precisely because repurposing often occurs inside larger drug development programs, across academic labs, and within confidential licensing negotiations.
The senior research team and subject matter experts at Verified Market Intelligence document limitations openly so readers can assess the scope and confidence of the analysis. We flag where data are incomplete, describe the provenance of clinical and commercial inputs, and note where coverage of small biotech collaborations, off-label prescribing practices, or proprietary compound libraries is inherently partial.
| Parameters | Limitations |
|---|---|
| Data availability for repurposing pipelines | Clinical and preclinical repurposing activities are frequently embedded in broader development portfolios, and many early stage efforts are conducted in academic labs or startup collaborations that do not publish full protocols or outcomes, limiting visibility into true pipeline breadth. |
| Regulatory pathway and approval outcomes | Regulatory interactions for repositioned indications follow diverse routes including supplemental approvals and off-label use, and public records do not always capture negotiated label expansions or conditional approvals that affect commercial potential. |
| Primary sample reach among stakeholders | Key participants such as small biotechs, academic spinouts, and proprietary compound libraries are less likely to participate in primary interviews, creating uneven coverage of discovery stage repurposing compared with larger pharmaceutical licensing deals. |
| Segment level detail by therapeutic area and modality | Therapeutic area reporting is challenged when a single molecule is repurposed across diverse indications or when modality shifts occur from small molecule to biologic adjacencies, reducing comparability across segments. |
| Commercial pricing and reimbursement signals | Pricing trajectories for repurposed drugs are confounded by legacy price structures, off-label prescribing, and heterogeneous payer responses to new indications, so published price lists and reimbursement decisions do not uniformly predict market uptake. |
Data Mining
Every Verified Market Intelligence study begins with data mining, the disciplined gathering of the raw evidence on which the entire Drug Repurposing Market analysis is built. Our research team treats this stage as the foundation of accuracy, because a forecast is only ever as sound as the information that feeds it. Before any number is modelled, analysts assemble a wide and deliberately diverse body of evidence so that no single viewpoint can distort the picture.
Data mining at Verified Market Intelligence draws on a repository built over many years that now spans more than six million datapoints. Analysts pull from structured and unstructured sources alike, ranging from company filings and financial statements to patents, trade records, regulatory disclosures and specialist databases. This breadth matters, because a signal seen in one source becomes far more trustworthy once it is confirmed in several others, and the habit of cross referencing begins the moment collection starts.
The team organises what it gathers into clear themes so the evidence can be interrogated rather than simply stored. Typical streams include the following.
- Industry and company records such as annual reports, investor presentations and earnings commentary that show how participants describe their own performance and priorities.
- Public and regulatory information including filings, standards documents and policy releases that shape how the sector can operate.
- Commercial and proprietary databases that supply pricing, shipment, capacity and trade figures at a level of detail rarely available in the open domain.
- News, patents and technical literature that surface early signals of innovation, investment and competitive movement.
As evidence accumulates, analysts begin to weigh it. Sources are judged on their authority, their recency and their independence, and anything that cannot be corroborated is set aside rather than allowed to influence the model. This early filtering keeps weak or promotional material from quietly shaping later conclusions, and it helps the team identify the questions that secondary reading alone cannot answer and that will later be carried into primary interviews.
Data mining is therefore far more than collection. It is the stage where the scope of the study is framed, the value chain is mapped, and an initial view of the participants and forces takes shape. By the time the raw evidence is handed to the next phase, it has already been sorted, screened and structured, giving every later estimate a defensible starting point and a clear trail back to its origin.
Because the repository is refreshed continually, data mining is never treated as a one time event. As new filings, quarterly results and trade figures appear, they are folded into the evidence base and the earlier picture is revisited in light of them. Analysts also record where each datapoint came from and when it was captured, so the provenance of every input stays visible. This twin habit of constant updating and careful sourcing keeps the study current and ensures that the foundation beneath every later stage reflects the most recent reality rather than a snapshot frozen at the start of the work.
Secondary Research
Secondary research is the stage where Verified Market Intelligence turns the evidence gathered during data mining into a structured understanding of the market under study. Analysts work through the assembled material methodically, building a first complete view of the Drug Repurposing Market before any primary conversation takes place. The aim is to enter those later interviews already informed, so expert time is spent confirming and refining rather than explaining the basics.
During this phase the team sizes the broad opportunity, maps how value moves from raw inputs through to the end user, and identifies the companies that shape supply and demand. Historical performance is reconstructed year by year so the trajectory is understood before it is projected forward. Equal attention is paid to the forces acting on the sector, including regulation, pricing behaviour, technology shifts and the wider economic backdrop.
Verified Market Intelligence draws its secondary evidence from sources chosen for reliability rather than convenience. These commonly include the following.
- Official statistics and association data from government bodies and industry groups that give a dependable baseline for volumes and value.
- Company disclosures such as annual reports, regulatory filings and earnings transcripts that show how leading participants perform and position themselves.
- Trade and technical literature that explains how products are made, priced and adopted across different applications.
- Reputable databases and the firm repository that together supply the depth needed to break the market down by segment and region.
As the picture takes shape, analysts reconcile figures that disagree. Two credible sources will rarely report exactly the same number, and the team treats those differences as useful rather than awkward. By examining why estimates diverge, analysts reach a considered position instead of simply averaging the available figures, and every claim that carries into the model is traced back to its origin so the reasoning can be reviewed at any point.
Secondary research also defines the boundaries of the study with care. Analysts state clearly what belongs inside the scope and what sits just outside it, which keeps later estimates consistent and prevents adjacent categories from inflating the numbers. Just as importantly, the stage exposes the questions that published material cannot answer, such as live pricing, real adoption rates and the forward intentions of buyers and suppliers. These open questions become the agenda for primary research, so direct engagement is focused exactly where it adds the most value.
The output of this stage is a documented evidence base rather than a loose collection of notes. Each figure is tied to its source, each assumption is written down, and the points that still need confirmation are flagged for the next phase. This discipline means the secondary view can be audited at any time and handed forward without loss of context. It also gives the research team a shared reference, so everyone working on the study is reasoning from the same well organised body of evidence rather than from individual interpretations.
Primary Research
Primary research is where Verified Market Intelligence tests its developing view against the people who live in the market every day. The secondary stage produces a strong and well sourced picture, yet some of the most important inputs, such as current pricing, true adoption levels and the real intentions of buyers and suppliers, can only be confirmed through direct conversation. This stage closes that gap for the Drug Repurposing Market.
Our research team engages both sides of the market so no single perspective dominates. On the demand side analysts speak with the organisations and individuals who purchase and use the products and services in question. On the supply side they engage the companies that design, manufacture and distribute them. Hearing both allows the team to reconcile what sellers expect with what buyers actually do, which is often where the most valuable insight is found.
Participants are selected for relevance rather than ease of access, and they typically include the following.
- Industry leaders and strategy owners who can explain direction, investment priorities and competitive intent.
- Product, sales and channel managers who see pricing, demand and distribution at close range.
- Distributors, integrators and channel partners who understand how products reach the end user and where friction appears.
- End users and independent specialists who provide an unfiltered view of adoption, satisfaction and unmet need.
Interviews are structured so answers can be compared across respondents, yet they remain open enough to surface issues the team did not anticipate. Analysts probe the assumptions formed during secondary research, asking participants to confirm, challenge or refine them. When a respondent contradicts an earlier finding, that tension is pursued rather than ignored, because it usually points to something the published record has missed or oversimplified.
The evidence collected here does more than validate, it calibrates. Pricing ranges are sharpened, segment definitions are adjusted to match how the market really behaves, and growth expectations are grounded in the plans of the companies that will actually deliver them. By the close of primary research the team holds a view that has been built from published evidence and then confirmed by the practitioners within the market, and that combination of breadth and first hand depth is what gives the final estimates their credibility.
Primary research is also where the human reality of the market enters the analysis. Numbers describe what is happening, but practitioners explain why, and that reasoning often reshapes how a trend should be read. A pricing shift may reflect a single contract rather than a lasting move, and a slowdown may mask strong underlying demand held back by supply. By listening closely to the people involved, Verified Market Intelligence captures these nuances and carries them into the model, so the study reflects not just the figures but the forces behind them.
Subject Matter Expert Advice
Before any estimate is finalised, Verified Market Intelligence places its findings in front of subject matter experts whose careers have been spent inside the sector under study. These specialists act as an independent check on the analysis, bringing a depth of judgement that no dataset can fully capture. Their role is not to replace the evidence but to interpret it, adding the context that turns sound numbers into genuine understanding of the Drug Repurposing Market.
Experts review the work at the points where experience matters most. They examine how the market has been defined, whether the segmentation reflects how the industry truly organises itself, and whether the drivers and restraints have been weighted sensibly. Because they have watched the sector evolve, they can tell quickly when a finding feels right and when something deserves a second look.
Their guidance typically sharpens the analysis in several ways.
- Validation of structure, confirming that segment and regional breakdowns match real commercial behaviour.
- Calibration of drivers, ensuring the forces shaping growth are neither overstated nor overlooked.
- Context on competition, clarifying how leading participants actually compete and where advantage is concentrated.
- A reality check on the outlook, testing whether the projected direction is consistent with what practitioners expect.
This dialogue is deliberately critical. Analysts present their reasoning and invite challenge, and where an expert disagrees the team revisits the underlying evidence rather than defending a conclusion. By the time expert review is complete, the findings carry not only the weight of data but the endorsement of seasoned judgement, which is exactly what a reader needs in order to act with confidence.
Expert involvement is documented alongside the rest of the evidence, so a reader can see that the conclusions were tested by independent specialists rather than formed in isolation. This openness is part of how Verified Market Intelligence earns trust. When a senior practitioner has reviewed the structure, the drivers and the outlook and found them sound, the analysis carries a credibility that figures alone can never provide.
Quality Check
Quality control runs through every Verified Market Intelligence study, and the dedicated quality check is where that discipline becomes explicit. Before any figure is allowed into the model, it must pass a structured screening that tests the strength of its source, its consistency with other evidence and its fit with the defined scope of the Drug Repurposing Market. The purpose is simple, only verified information should shape the conclusions a reader will rely on.
The check works in stages so weaknesses are caught early rather than discovered late. Analysts first confirm that each source is credible and current, giving more weight to primary evidence and authoritative records than to material that cannot be traced. Duplicate inputs are removed so a single figure repeated across several outlets is not mistaken for independent confirmation. Conflicting datapoints are then reconciled, with analysts examining why estimates differ and resolving the difference on the basis of reasoning rather than convenience.
Typical screens applied at this stage include the following.
- Source credibility, weighing the authority, independence and recency of every input.
- Internal consistency, checking that segment figures sum correctly to regional and total values.
- Outlier review, investigating any number that sits far from the supporting evidence before it is accepted or rejected.
- Scope alignment, confirming that each datapoint belongs inside the boundaries set for the study.
Consistency checks receive particular attention because they protect the integrity of the whole model. When the parts no longer agree with the whole, the team treats it as a signal that an assumption or an input needs revisiting. Nothing is smoothed over to make the figures fit. Instead the discrepancy is traced to its cause and corrected at the root, which keeps the final estimates honest and internally coherent.
This stage also documents the decisions taken, so the reasoning behind every accepted or rejected figure can be reviewed later. That transparency is deliberate. It means the analysis can withstand scrutiny long after publication, and that any reader, however demanding, can follow the logic from raw input to final estimate.
The quality check is applied throughout the study rather than saved for the end, so problems are corrected while they are still small and inexpensive to fix. Each pass tightens the evidence a little further, and by the time the figures reach the modelling stage they have been examined from several directions. This steady and repeated scrutiny is what allows Verified Market Intelligence to stand behind its numbers and to show, on request, exactly why each one was accepted.
Final Review
The final review is the last gate a Verified Market Intelligence study passes before publication, and it is conducted by senior analysts who were not responsible for building the individual estimates. This separation is intentional. A fresh and experienced eye is far more likely to notice an inconsistency or an unsupported claim than the analyst who has lived with the numbers for weeks.
At this stage the report is examined as a whole rather than in pieces. Reviewers read the narrative, inspect the figures and study the charts together, checking that the story the words tell is the same story the data supports. A forecast mentioned in the text must match the model behind it, and a trend described in the analysis must be visible in the evidence. Where the two drift apart, the report is returned for correction.
The review concentrates on a few decisive questions.
- Coherence, confirming that narrative, numbers and visuals all tell a single consistent story.
- Evidence, ensuring every material claim can be traced to a verified source or a primary input.
- Clarity, checking that the findings are expressed plainly enough to inform a real decision.
- Completeness, verifying that the scope agreed at the outset has been fully addressed.
Reviewers also weigh the analysis against their own knowledge of the sector and against the guidance gathered from subject matter experts. If a conclusion feels out of step with how the market behaves, they challenge it and ask for the supporting reasoning to be shown rather than assumed. Only when the analysis answers those challenges convincingly does it move forward.
Presentation receives the same care as substance. The Drug Repurposing Market report is checked for consistent terminology, accurate labelling and a structure that lets a reader find and trust the information quickly. Small errors are treated seriously, because they erode confidence in the larger findings. When the final review is complete, Verified Market Intelligence has confirmed that the study is accurate, internally consistent and ready to be relied upon, and only then is it released to the reader.
Only once the report has cleared every question raised in this review is it approved for release. Nothing is published on the strength of effort alone, and a study is held back rather than issued with an unresolved doubt. This willingness to pause until the analysis is genuinely ready is central to how Verified Market Intelligence protects the reader, because a decision taken on the back of the report deserves a foundation that has been checked, challenged and confirmed.
Data Triangulation
Data triangulation is the method Verified Market Intelligence uses to confirm a finding from more than one independent direction before it is accepted. Rather than relying on any single estimate, the team brings together what the primary interviews revealed, what the secondary evidence established and the accumulated knowledge held within the firm. When these separate lines of enquiry point to the same answer, confidence is high. When they disagree, the difference is investigated until it can be explained and resolved.
The diagram above shows how these inputs converge. Primary engagement with the demand and supply side, a broad base of secondary reports and websites, and the firm own repository each contribute a distinct view of the Drug Repurposing Market. Triangulating across them removes the bias that any one source can carry and produces estimates that hold up under scrutiny. It is this insistence on agreement from multiple angles that lets the market size, share and growth figures in this report be presented with confidence.
Bottom-Up Approach
The bottom-up approach builds the size of the market from the ground upward. Verified Market Intelligence begins with the smallest reliable units of demand, then aggregates them step by step into the complete picture. Volumes are estimated for each product segment within each region, combined with realistic prices, and summed across every region to reach the total value of the Drug Repurposing Market.
As the diagram shows, the geographic split of volume sits at the base, segment level pricing is applied above it, and the regional totals are added together to produce the overall figure stated in USD. Because every layer is grounded in observed demand and validated pricing, the method stays close to commercial reality and keeps each part of the total traceable. Primary inputs from demand and supply side experts anchor the volumes and prices, while secondary sources and the firm repository provide the supporting detail.
Top-Down Approach
The top-down approach works in the opposite direction to the bottom-up build and is used to validate it. Verified Market Intelligence starts from the total value of the Drug Repurposing Market, then allocates that figure downward, first across the major segments, then across countries, and finally to each sub segment within a country. The total itself is confirmed through primary conversations with demand and supply side experts before it is divided.
Reading the two methods against each other is what gives the estimates their strength. As the diagram shows, the top-down split should arrive at the same segment and regional values that the bottom-up build produced from the ground up. Where the two agree, the figure is confirmed. Where they differ, analysts trace the cause and reconcile it before publication, so the numbers in this report stay consistent whichever direction they are viewed from.
10 more chapters · sign in to continue
Keep reading the Drug Repurposing Market report
You’re reading the free preview. Sign in to unlock the remaining 10 chapters and 124 sections - segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Merck & Co. Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Takeda Pharmaceutical Company Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Gilead Sciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Amgen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Small Molecule Drugs57.7
- Biologics10.8
- Peptides18.9
- Nucleic Acid-based Drugs12.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG23.0
- Pfizer Inc.18.2
- Roche Holding AG3.9
- Johnson & Johnson9.1
- AstraZeneca plc9.7
- GlaxoSmithKline plc8.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe24.0
- Asia Pacific20.2
- Latin America14.0
- Middle East and Africa10.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 84 | 88 | 92 | 85 | 81 | 88 | 86 |
| Pfizer Inc. | 77 | 88 | 79 | 81 | 93 | 70 | 81 |
| Roche Holding AG | 74 | 80 | 84 | 81 | 76 | 84 | 80 |
| Johnson & Johnson | 62 | 63 | 76 | 79 | 80 | 61 | 70 |
| AstraZeneca plc | 59 | 55 | 68 | 61 | 67 | 55 | 61 |
| GlaxoSmithKline plc | 53 | 50 | 52 | 48 | 50 | 53 | 51 |
| Sanofi S.A. | 54 | 40 | 46 | 51 | 58 | 45 | 49 |
| Bristol-Myers Squibb Company | 54 | 57 | 58 | 59 | 54 | 57 | 57 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Pfizer Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Pfizer Inc. | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Roche Holding AG | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Johnson & Johnson | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| AstraZeneca plc | − | − | − | − | ✓ | − |
| GlaxoSmithKline plc | − | − | ◐ | − | − | ◐ |
| Sanofi S.A. | ◐ | − | − | ◐ | ◐ | − |
| Bristol-Myers Squibb Company | ◐ | ◐ | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Drug Type in North America, then scale across Drug Repurposing Market — a $0M beachhead inside a $5M market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Small Molecule Drugs
Best fit — highest urgency & budget in Drug Type.
Biologics
Strong fit — clear ROI and a fast path to value.
Peptides
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Repurposing Approach
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Drug Repurposing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Drug Repurposing Market is a durable-growth opportunity — $6M by 2033, compounding at 7.1%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.1% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Drug Repurposing Market — a $6M market by 2033. Plan: grow share from 8.0% to 16.7%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 16.7% | Behind |
| Revenue | $1M | $1M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.7% | 45.6% | At risk |
| Customer retention | 84.4% | 96.8% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $0M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Drug Repurposing Market conversation — a $8M market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Drug Repurposing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Drug Repurposing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Drug Reprofiling Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportDrug Repositioning Service Market
Market size, share, segmentation and regional forecast.
$705M market · 2025 base year
View reportDrug Repositioning Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDrug-releasing Pump Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDrug Reference App Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDrug Reconstitution System Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportDrug Reconstitution Device Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportDrug Preclinical CRO Services Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportDrug & Pharmaceuticals & Cosmetics Retail Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportHigh Purity Hydrogen Peroxide Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportDrug of Abuse Urine Testing Instrument Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportDrug of Abuse Urine Tester Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy